Investment Plan for Europe: EIB grants financing to Apeiron

The European Investment Bank (EIB) will provide financing of EUR 25 million to the Austrian biotech company Apeiron Biologics AG (Apeiron). The financing will support the development of new pharmaceutical products to treat cancer, particularly a rare type affecting children. The transaction with Apeiron was made possible by the support of the “European Fund for Strategic Investments” (EFSI). EFSI is the central pillar of the “Investment Plan for Europe”, in which the EIB Group and the European Commission as strategic partners aim to boost the competitiveness of the European economy. (read more…)

Press release

Presseaussendung